DeJesus E, Towner WJ Jr, Gathe JC, Cash RB, et al. Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals. J Acquir Immune Defic Syndr 2024 Sep 9. doi: 10.1097/QAI.0000000000003524.
PMID: 39250331